Daphne N Dorst
Overview
Explore the profile of Daphne N Dorst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
CD64 as novel molecular imaging marker for the characterization of synovitis in rheumatoid arthritis
Theeuwes W, Di Ceglie I, Dorst D, Blom A, Bos D, Vogl T, et al.
Arthritis Res Ther
. 2023 Aug;
25(1):158.
PMID: 37653557
Background: Rheumatoid arthritis (RA) is one of the most prevalent and debilitating joint diseases worldwide. RA is characterized by synovial inflammation (synovitis), which is linked to the development of joint...
2.
Dorst D, Smeets E, Klein C, Frielink C, Geijs D, Trajkovic-Arsic M, et al.
Mol Pharm
. 2023 Jul;
20(8):4319-4330.
PMID: 37485886
Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in...
3.
Smeets E, Dorst D, Franssen G, van Essen M, Frielink C, Stommel M, et al.
Cells
. 2023 Jul;
12(10).
PMID: 37408254
Fibroblast activation protein (FAP), expressed on cancer-associated fibroblasts, is a target for diagnosis and therapy in multiple tumour types. Strategies to systemically deplete FAP-expressing cells show efficacy; however, these induce...
4.
Dorst D, van Caam A, Vitters E, Walgreen B, Helsen M, Klein C, et al.
Int J Mol Sci
. 2021 Dec;
22(23).
PMID: 34884484
Systemic sclerosis (SSc) is a rare, severe, auto-immune disease characterized by inflammation, vasculopathy and fibrosis. Activated (myo)fibroblasts are crucial drivers of this fibrosis. By exploiting their expression of fibroblast activation...
5.
Dorst D, Boss M, Rijpkema M, Walgreen B, Helsen M, Bos D, et al.
Pharmaceutics
. 2021 Nov;
13(11).
PMID: 34834283
Macrophages play a crucial role in the initiation and progression of rheumatoid arthritis (RA). Liposomes can be used to deliver therapeutics to macrophages by exploiting their phagocytic ability. However, since...
6.
Dorst D, Rijpkema M, Buitinga M, Walgreen B, Helsen M, Brennan E, et al.
Rheumatology (Oxford)
. 2021 Aug;
61(7):2999-3009.
PMID: 34450633
Objective: Activated synovial fibroblasts are key effector cells in RA. Selectively depleting these based upon their expression of fibroblast activation protein (FAP) is an attractive therapeutic approach. Here we introduce...
7.
Dorst D, Rijpkema M, Boss M, Walgreen B, Helsen M, Bos D, et al.
Rheumatology (Oxford)
. 2020 Aug;
59(12):3952-3960.
PMID: 32734285
Objective: In RA, synovial fibroblasts become activated. These cells express fibroblast activation protein (FAP) and contribute to the pathogenesis by producing cytokines, chemokines and proteases. Selective depletion in inflamed joints...